What Are Peptides?

Peptides are molecules made up of 2 to 50 amino acids linked together in a chain. They are smaller than proteins (which are longer chains) but work in a similar way — binding to receptors and triggering specific biological responses.

Your body naturally produces hundreds of peptides to regulate everything from hunger and metabolism to sleep, mood, tissue repair, and hormone release. Synthetic peptides mimic or enhance these natural signals.

Unlike anabolic steroids, most peptides work by stimulating your body's own production of hormones or natural repair processes — rather than replacing them directly.

Receptor binding

Peptides bind to specific receptors on cell surfaces, like a key in a lock. Each peptide targets a specific receptor type, causing a precise biological effect.

Signaling cascades

Once bound, the receptor triggers a cascade of cellular signals. GLP-1 agonists, for example, signal the brain to suppress appetite and signal the pancreas to release insulin.

Targeted effects

Because peptides work through specific receptors, they tend to produce targeted effects with fewer systemic side effects than many traditional medications.

The peptide world is large but most users encounter five practical categories. The GLP-1 class is the most clinically validated and the easiest to evaluate, so we open with its data.

A first-pass map between common goals and the peptide most users start with. This is not a substitute for the screening guide — clear contraindications first, then return to this table.

The five categories above are universal — receptor-level biology doesn't change between countries. What changes in the Philippines is which categories you can access cleanly through the regulated medical system, and which require operating in research-grade territory. This is the practical map every Manila reader needs before going further into the library.

Class 01 GLP-1 agonists (Retatrutide, Tirzepatide, Semaglutide) are the most clinically validated and the most accessible in PH. Tirzepatide as Mounjaro and semaglutide as Ozempic and Wegovy are FDA Philippines registered and prescribable through endocrinology clinics at Makati Medical Center, St. Luke's BGC, The Medical City, and Manila Doctors Hospital. Mercury Drug and Watsons stock the FDA-registered pens at most major Metro Manila branches. Retatrutide is not yet registered and lives in research-grade territory. Class 02 Growth Hormone peptides (Tesamorelin, recombinant somatropin) are FDA registered for specific indications — typically only prescribed through endocrinology consults at the same hospital network.

Classes 03 through 05 — Healing & Recovery (BPC-157, TB-500, GHK-Cu, KPV), Anti-Aging & Longevity (Epitalon, NAD+, MOTS-c), Nootropics & Mood (Semax, Selank, DSIP), and Cosmetic & Tanning (SNAP-8, Melanotan I and II) — are not FDA Philippines registered and are sourced through international research-peptide suppliers under personal-import rules. Bureau of Customs treats single-vial personal shipments under personal-use thresholds; bulk volumes draw scrutiny. Compounding pharmacies in Makati and BGC can prepare bacteriostatic water and sterile syringes when written by a physician, but they do not stock the research peptides themselves. The bloodwork ecosystem at Hi-Precision Diagnostics and Makati Medical Center outpatient — IGF-1, full hormone panels, HbA1c, lipid panels — is what makes Manila a strong base for actually monitoring whether any of these protocols are working: a starter panel runs USD 80 to 120 versus USD 400 to 600 in the United States.

The first peptide I touched personally in Manila was tirzepatide. I was sitting at a Starbucks in Greenbelt 5 in late October 2025, two weeks after landing from Austin, reading the SURMOUNT-1 trial data on my laptop and pricing options. The arithmetic was striking. A 4-pen Mounjaro 5mg box at the Mercury Drug counter at Glorietta 4 ran USD 290. The same box in Texas ran USD 1,000+. The endo consult at Makati Medical Center that wrote the script ran USD 75. The starter bloodwork panel at Hi-Precision in Makati ran USD 95. Total cost to start a clinically validated weight-loss protocol with full medical supervision: roughly USD 460 for the first month.

What surprised me most was the routine itself, not the substance. Sunday evening, 9pm, in my BGC condo. Pen out of the fridge for 15 minutes to come to room temperature. Single subcutaneous injection in the abdomen, alcohol swab before and after. Pen back in the fridge. Total elapsed time: under three minutes. The first three doses were the hardest — mild nausea Monday mornings, suppressed appetite throughout the week, the metabolic feedback you read about in every clinical paper but feel differently when it's your own body. Six weeks in I'd lost 8 pounds. Eight weeks in the bloodwork showed HbA1c drop from 5.6 to 5.3 and a 22% reduction in fasting insulin. The numbers told the truth the scale couldn't.

The point of this anecdote isn't the substance — it's the access. Manila's combination of FDA-registered GLP-1 inventory at Mercury Drug, cash-pay endocrinology consults at Makati Med and St. Luke's BGC, and same-day bloodwork at Hi-Precision makes the regulated medical pathway genuinely usable for foreigners and locals alike. The research-grade peptides that come up later in this site — BPC-157, GHK-Cu, MOTS-c, kisspeptin — operate in a different supply chain, but the regulated entry point is real, accessible, and clinically validated. Most readers should start there before considering anything else.

• SRC-01Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022;387:205–216. DOI: 10.1056/NEJMoa2206038 · PubMed: 35658024 — pivotal Phase 3 trial of tirzepatide showing 22.5% weight loss at the highest dose.
• SRC-02Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183 · PubMed: 33567185 — pivotal STEP-1 trial of semaglutide showing 14.9% weight loss.
• SRC-03Jastreboff AM et al. Triple–hormone-receptor agonist retatrutide for obesity (Phase 2). NEJM 2023;389:514–526. DOI: 10.1056/NEJMoa2301972 · PubMed: 37366315 — Phase 2 retatrutide trial showing 24.2% weight loss at 48 weeks.
• SRC-04Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des 2011;17(16):1612–32. PubMed: 21548867 — foundational BPC-157 mechanism review.
• SRC-05FDA Philippines Verification Portal. verification.fda.gov.ph — primary registry for FDA PH-registered drug products including Ozempic, Wegovy, Mounjaro, and Tesamorelin.